NCT04968106 - Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 7, 2022

Primary Completion Date

March 31, 2026

Study Completion Date

October 31, 2027

Conditions

Resectable Sarcoma

Interventions

DRUG

Doxorubicin

Doxorubicin will administered by intravenous infusion on day 1 every 3 weeks (75 mg/m²) up to 3 cycles

DRUG

Ifosfamide

Ifosfamide will be administered by intravenous infusion over 3 days every 3 weeks (9 g/m²) up to 3 cycles

DRUG

INCMGA00012

Retifanlimab will be administered by intravenous infusion on day 1every 3 weeks (375 mg) up to 3 cycles

Trial Locations (4)

RECRUITING

Institut Bergonié, Bordeaux

WITHDRAWN

Institut Gustave Roussy, Villejuif

RECRUITING

Centre Léon Bérard, Lyon

NOT_YET_RECRUITING

Institut Curie, Paris